tbuckley/cabot-search huggingface dataset:
Chronic Occlusive Arterial Disease of Extremities
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
LETTER FROM NEW YORK.
Authors: None P. B. P.
Journal: JAMA (1890)

(FROM OUR OWN CORRESPONDENT.) <i>Dr. S. Baruch at the Meeting of the Section on Practice of the Academy of Medicine—Cold Baths in Typhoid Fever</i>. At the February meeting of the Section on Practice of the Academy of Medicine, Dr. S. Baruch, who was not present at the meeting of the Academy a month before, when the treatment of typhoid fever was discussed, made a stirring and forcible plea for the systematic use of cold baths in this disease. However favorable some of our individual statistics might be, he said, the figures of the Board of Health reports demanded, in language more eloquent than words, that the profession should adopt some means that would enable them to make a more favorable showing. From 25 to 40 per cent, was the death-rate from typhoid in our American cities, and according to Dr. Delafield's investigation 26 per cent. was the death-rate in recent
Intense Emotions in an Intensive Care Ward
Journal: JAMA (1971)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue Access Provided by Korea University Medical Library JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account
'Bubble boy' reacts well to marrow transplant
Authors: K. Simmons
Journal: JAMA (1983)

Twelve years of life in a plastic isolator bubble may be part of the past for David, the world's longest survivor of untreated severe combined immunodeficiency (SCID). On Oct 21, David received a bone marrow transplant from his 15-year-old sister at Texas Children's Hospital, Houston. The treatment— if successful—will free him to live in the open environment. It now appears that the risk period for the possible occurrence of acute graft v host disease (GVHD) has passed and, according to William T. Shearer, MD, Baylor College of Medicine, Houston, who heads the medical team caring for David, "his condition is excellent. We're very pleased with his medical progress and frame of mind. We're optimistic at this point." The signs of acute GVHD that the physicians were watching for in the first ten or so days were fever, rash, swollen glands, liver enlargement, and elevated liver enzymes. In an effort to
THE SPECIFIC NATURE OF THE ANTITOXIC SUBSTANCES IN THE BLOOD OF ANIMALS RENDERED IMMUNE AGAINST THE BACILLUS TYPHOSUS AND THE BACILLUS COLI COMMUNIS.
Journal: JAMA (1896)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
EPIDEMIC INFLUENZA; COMMONLY CALLED "THE GRIP."
Journal: JAMA (1994)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Hemodynamic evaluation of the addition of isosorbide-5-mononitrate to nadolol in cirrhotic patients with insufficient response to the beta- blocker alone
Authors: C Merkel
Journal: Hepatology (1997)

The association beta-blockers plus isosorbide-5-mononitrate (I5M) has been proposed for the treatment of portal hypertension in patients with insufficient response to beta-blockers alone, according to hemodynamic criteria. The mechanism of action in these patients is not clearly defined. Fifteen patients with cirrhosis and esophageal varices were evaluated by hepatic venous pressure gradient (HVPG) measurement and duplex-Doppler ultrasonography before and after 1 month of treatment with nadolol. Nine patients who did not exhibit a decrease in HVPG to 12 mm Hg or a percent decrease greater than 20% were classified as poor responders, and were studied again with the same methodology after 3 months of chronic administration of nadolol + I5M 20 mg twice per day. In poor responders, mean HVPG decrease after nadolol was 8.9% +/- 2.8%, and after the combination, it was 25.7% +/- 1.7% (P = .004). All patients except one became good responders to the association. Portal blood flow (PBF) decreased significantly after nadolol (P = .004), and remained unchanged after the addition of nitrates. Resistance to portal blood flow (RPBF) increased after nadolol (P = .02) and returned to baseline values during combined treatment (P = .03). In good responders, an adequate decrease in HVPG was associated with a decrease in PBF (P = .06) but no change in RPBF. A wide spectrum of combined changes in PBF and in RPBF after nadolol was observed in poor responders, ranging from no change in either parameter to a marked decrease in PBF counterbalanced by a marked increase in RPBF. The addition of I5M was followed in most cases by larger effects on resistance than on flow. Doppler parameters were not significantly correlated with the HVPG response to nadolol alone or associated with I5M. It is concluded that good hemodynamic responders to nadolol differ from poor responders in the lack of increase in RPBF after the drug. The addition of nitrates to nadolol is effective in decreasing portal pressure in most poor responders to nadolol alone. A decrease in outflow resistance is the main mechanism involved. (Hepatology 1997 Jul;26(1):34-9)
“Pneumocystosis revealing immunodeficiency secondary to<i>TERC</i>mutation.” Raphael Borie, Caroline Kannengiesser, Flore Sicre de Fontbrune, David Boutboul, Laure Tabeze, Florence Brunet-Possenti, Elodie Lainey, Marie Pierre Debray, Aurélie Cazes and Bruno Crestani.<i>Eur Respir</i><i>J</i>2017; 50: 1701443.
Journal: European Respiratory Journal (2018)
ANGIOMA SERPIGINOSUM.
Authors: W. FRAIN-BELL
Journal: British Journal of Dermatology (1957)

Journal Article ANGIOMA SERPIGINOSUM. Get access W. FRAIN‐BELL, M.D., M.R.C.P.(Ed). W. FRAIN‐BELL, M.D., M.R.C.P.(Ed). Senior Registrar, St. John's Hospital for Diseases of the Skin, London Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 69, Issue 7-8, 1 July 1957, Pages 251–268, https://doi.org/10.1111/j.1365-2133.1957.tb13265.x Published: 01 July 1957
37th Annual Postgraduate Assembly of The Endocrine Society
Journal: Endocrine Reviews (1985)

Journal Article 37th Annual Postgraduate Assembly of The Endocrine Society Get access Endocrine Reviews, Volume 6, Issue 3, 1 July 1985, Pages 487–489, https://doi.org/10.1210/edrv-6-3-487 Published: 01 July 1985
HEMATOGENOUS TUBERCULOSIS.
Journal: JAMA (1902)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Development of of pseudoanemia in marathon runners during a 20-day road race
Authors: R. H. Dressendorfer
Journal: JAMA (1981)

We measured RBC count, blood hemoglobin concentration, and related hematologic factors in 12 male marathon runners during a 20-day, 312-mile road race. The RBC and hemoglobin levels decreased significantly, from 5.17 million per cubic millimeter and 16.0 g/dL, respectively, to 4.36 million per cubic millimeter and 13.4 g/dL. Although the runners became marginally anemic during the race, their running speeds were not significantly changed. There were no abnormal clinical signs other than rare instances of hematuria. This study indicates that a sudden increase in long-distance running mileage above the regular training level may cause "sports anemia," a functional pseudoanemia that, in mild cases, does not impair endurance performance. (<i>JAMA</i>1981;246:1215-1218)
Errata: Vol. 54, No. 10
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
DEATHS
Journal: JAMA (1960)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Soft water, heart attacks, and stroke
Authors: A. G. Shaper
Journal: JAMA (1974)

HEART attacks and strokes are the major causes of death in the United States, as in most developed countries of the world. The search for factors that might be concerned with the causation of these diseases has been intense and has gone on for many years. Many elements have already been found to be closely associated with the risk of heart attacks or stroke, and examination of individuals or populations may reveal the presence of these "risk factors." High blood cholesterol levels, high blood pressure, cigarette smoking, and diabetes mellitus are well established as risk factors in cardiovascular disease. Obesity and lack of vigorous physical activity are certainly involved in determining who suffers and who does not. As if this list was not enough, there has been increasing evidence in the past 15 years of yet another factor that appears to play an important role in influencing cardiovascular disease:<i>the</i>
Abstract 4974: Metformin has an anti-cancer effect by repressing TWIST/N-cadherin signaling
Authors: Rongbin Ge, Zongwei Wang, Aria Olumi
Journal: Cancer Research (2012)

Abstract Introduction and Objective Metformin, one of the most commonly used medications for treatment of type 2 diabetes, has emerged as a potential anticancer agent. The molecular mechanisms associated with the anti-cancer effect of metformin are poorly understood. We demonstrate, for the first time, that metformin inhibits prostate cancer proliferation through suppression of TWIST/N-cadherin signaling pathway. Methods RTαPCR, Western blot, immunofluorescence assays and confocal microscopy were applied to evaluate protein expression level. MTS assay and FACS analysis were applied to determine cellular proliferation. N-cadherin expression vectors were transfected into PC3 prostate cancer cells to establish stable cells with over-expression of N-cadherin. Metformin-resistant prostate cancer cells were established by exposure to higher concentrations (10mM) of metformin over 4 weeks. Results Treatment with metformin (5mM) inhibited proliferation in three different types of cancer cells (PC3-prostate cancer cells; T24-bladder cancer cells and 786-O- kidney cancer cells). Metformin treatment suppressed expression of N-cadherin in all cell types. Similar findings were observed by confocal microscopy. Expression of E-cadherin was not affected by metformin. Metformin-mediated repression of N-cadherin was dose and time- dependent in prostate cancer cells. PC3 prostate cancer cells with stable over-expression of N-cadherin became resistant to metformin-mediated inhibition. Stable PC3 prostate cancer cells after selection for metformin became resistant to metformin-mediated inhibition, and the metformin-resistant cancer cells had slightly higher baseline level of N-cadherin. In addition, in the metformin-resistant cells, N-cadherin levels were unchanged after treatment with metformin. The expression of AKT and AP-1, the downstream molecules of N-cadherin, closely correlated with expression of N-cadherin after treatment with metformin. Moreover, we also found that metformin inhibited expression of TWIST-1, a transcriptional activator of N-cadherin. Similar findings were observed by confocal microscopy. Conclusions We demonstrate that Metformin's anti-cancer therapeutic effect may be mediated through repression of the TWIST/N-cadherin signaling pathway. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 4974. doi:1538-7445.AM2012-4974
Response
Authors: L. HORTON
Journal: JNCI Journal of the National Cancer Institute (1989)

Journal Article Response Get access LARRY HORTON LARRY HORTON Office of Public Affairs Stanford UniversityBldg. 170 Stanford, CA Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 81, Issue 17, 6 September 1989, Pages 1332–1334, https://doi.org/10.1093/jnci/81.17.1332-a Published: 06 September 1989
Mortality Following Inpatient Addictions Treatment
Authors: Richard D. Hurt
Journal: JAMA (1996)

<h3>Objective.</h3> —To determine the impact of tobacco- and alcohol-related deaths on overall mortality following inpatient treatment for alcoholism and other nonnicotine drugs of dependence. <h3>Design.</h3> —Population-based retrospective cohort study. <h3>Setting.</h3> —Olmsted County, Minnesota (the Rochester Epidemiology Project), and the Inpatient Addiction Program (IAP) at Mayo Clinic, Rochester. <h3>Patients.</h3> —All 845 Olmsted County residents admitted to an inpatient addiction program for treatment of alcoholism and other nonnicotine drugs of dependence during the period 1972 through 1983. <h3>Methods.</h3> —Patients were followed up through the medical record linkage system of the Rochester Epidemiology Project through December 1994 to obtain vital status, and death certificates were obtained for those who died. The underlying cause of death was classified as alcohol related, tobacco related, both, or neither based on the classification from the Centers for Disease Control and Prevention. The observed number of deaths by underlying cause was compared with the expected number using cause-specific 1987 death rates for the white population of the United States. All-cause mortality was also compared with that expected for persons in the West North Central Region of the United States of like age, sex, and year of birth. Univariate and multivariate assessments were made to identify predictors of all-cause mortality from baseline demographic information. <h3>Results.</h3> —At admission, the mean (SD) age of the 845 patients was 41.4 (14.5) years, and 35% were women. Altogether, 78% had alcohol as their only nonnicotine drug of dependence and 18% had alcohol and other nonnicotine drugs of dependence, while 4% were classified as having a nonalcohol, nonnicotine drug dependence alone. At admission, 75% were current and 8% former cigarette smokers, 3% were current cigar or pipe smokers, and 2% were current users of smokeless tobacco. Follow-up after the index IAP admission totaled 8913 person-years (mean [SD] of 10.5 [5.6] years per patient). Death certificates were obtained for 96% (214) of the 222 patients who died. Of these 214 deaths, 50.9% (109) had a tobacco-related and 34.1% (73) had an alcohol-related underlying cause (<i>P</i>&lt;.001). The cumulative mortality significantly exceeded that expected (<i>P</i>&lt;.001); at 20 years, the observed mortality was 48.1% vs an expected 18.5%. Multivariate predictors of mortality, even after adjusting for expected mortality, were older age at admission (<i>P</i>&lt;.001) and male sex (<i>P</i>&lt;.001). <h3>Conclusions.</h3> —Patients previously treated for alcoholism and/or other nonnicotine drug dependence had an increased cumulative mortality that was due more to tobacco-related than to alcohol-related causes. Nicotine dependence treatment is imperative in such high-risk patients. (<i>JAMA</i>. 1996;275:1097-1103)
Myasthenia Gravis and Rheumatoid Spondylitis
Authors: James B. Carter
Journal: JAMA (1965)

RECENTLY, we observed a patient having myasthenia gravis and long-standing rheumatoid (ankylosing) spondylitis. The coexistence of these two relatively uncommon diseases was unusual in our experience, and a review of the English literature failed to reveal any previously reported cases. However, review of the case histories of the 857 patients having myasthenia gravis who were seen at the Mayo Clinic from 1934 to July 1964 yielded two other cases. These three cases are the subject of this report. <h3>Report of Cases</h3><h3>Case 1.—</h3> A 55-year-old married white man, an electrician, entered the hospital on March 13, 1964, because of diplopia and ptosis of the upper eyelids. The diplopia had begun in September 1962, but it had not become severe until December 1963, when the ptosis began. Myasthenia gravis had been diagnosed, and the patient had responded well to treatment with pyridostigmine (Mestinon) bromide. However, in February 1964 his symptoms had